iPill

iPill is a pill dispenser with a smartphone application, designed to directly address and combat the opioid crisis.

iPill has won numerous competitions, has been designated by the FDA as a "breakthrough" medical device, and received FDA Class I Registration.
iPill's serviceable addressable market is $10 billion annually.
iPill has been granted 3 patents and is the only pill dispenser on the market that is completely tamper-resistant and has insurance coverage.

We will not incur any irregular use of proceeds.

John Hsu MD, CEO & Co-Founder
Dr. Hsu, has practiced anesthesia and pain management for 28 years. Combining his knowledge of anesthesia, software and hardware, his latest innovation is using remote monitoring technology to ensure opioid prescription adherence to reduce opioid abuse and diversion. His company, iPill dispenser has 3 granted patents to fight the opioid epidemic and is FDA registered. Another company, he founded, Quivivepharma is concerned with drug development. It is combining oral opioids with an oral respiratory stimulant to counteract opioid induced respiratory respiratory depression. It is fast-tracked by the FDA and has 2 granted patents. He is devoted to making a social impact with projects that can save lives, improve healthcare, and reduce medical expenses.

Sherie Hsieh, BS, COO, Director & Co-Founder
Ms. Hsieh, a clinical toxicologist and Co-Founder of the iPill. She handles daily activities of the iPill. She has experience as director of marketing at Quivivepharma and was responsible for brand awareness and business development. Ms. Hsieh, leads her own private investment company.

Peter Weinstein PhD, JD, Director & Legal Counsel
Dr. Weinstein handles all aspects of Intellectual property, transaction, and corporate law. Dr. Weinstein currently is a Director of the company and advises the company on legal matters. His primary role is as CEO of Entralta currently and he commits 10 hours per week to iPill.

Price Per Share: $1.50